Article Text

Download PDFPDF

2022-RA-1312-ESGO Feasibility of carboplatin monotherapy versus carboplatin-paclitaxel in frail elderly epithelial ovarian cancer patients
  1. Tamara Yu1,
  2. Ronas Taner Kesmez2,
  3. MJ Flynn1,
  4. JA Ledermann1,
  5. M Lockley1,
  6. N MacDonald1,
  7. M McCormack1,
  8. S Nicum1,
  9. SM Crusz2,
  10. RE Miller1,2 and
  11. Eve Merry1
  1. 1University College Hospital, University College London Hospital NHS Foundation Trust, 235 Euston Road, NW1 2BU, London, UK
  2. 2St Bartholomew’s Hospital, Barts Health NHS Trust, West Smithfield, EC1A 7BE, London, UK


Introduction/Background Frail elderly patients with ovarian cancer (OC) are often treated with 3-weekly carboplatin (3wC) rather than carboplatin-paclitaxel (CP). Elderly Women with OC (EWOC)-1 trial demonstrated that 3-weekly carboplatin-paclitaxel (3wCP) achieved better survival outcomes and was more feasible (defined as the ability to complete 6 chemotherapy cycles without disease progression, death, or premature discontinuation due to toxicity) than 3wC in patients 70 years old (70 yo) with FIGO stage III/IV OC. We compared the feasibility of treatment with 3wC or 3wCP in frail elderly OC patients.

Methodology Data from two cancer centres was retrospectively analysed for newly-diagnosed stage III/IV OC patients 70 yo treated with 3wC or 3wCP. Frailty was scored using the Charlson-Comorbidity Index (CCI) and ECOG performance status. Toxicity was graded using CTCAE v5.0.

Results 107 patients received 3wC (n=31) or 3wCP (n=76, 2 receiving 3wC with weekly paclitaxel). Patients treated with 3wC rather than 3wCP were older ((median age 83 vs. 75 (p<0.001)) with more comorbidities ((median CCI 4 vs. 3 (p<0.001)). Treatment was discontinued for 4 of the 31 (13%) 3wC patients and 6 of the 76 (8%) patients who received 3wCP, with death and disease progression the most common reasons for discontinuation respectively, although the difference in discontinuation rate was not significant (p>0.05). Dose reductions occurred in 16% (5/31) of patients who received 3wC and 57% (43/76) of patients treated with 3wCP, most commonly due to haematological toxicity and peripheral neuropathy respectively.

Abstract 2022-RA-1312-ESGO Figure 1

Overview of toxicities leading to dose reduction and treatment discontinuation in 3wCP and 3wC cohorts

Conclusion In spite of the limitations of our retrospective analysis, 3wCP appears as feasible as 3wC monotherapy for frail 70 yo FIGO stage III/IV OC patients, in keeping with the EWOC-1 data, and should be considered in this cohort given that it has been shown to achieve better survival outcomes. Toxicity profiles differ and dose reductions may be required in each treatment arm.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.